{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:58:50Z","timestamp":1781650730316,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019711","name":"London Health Sciences Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020387","name":"Lung Cancer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The clinical demand for reirradiation is increasing; however, evidence for dose guidance to estimate normal tissue toxicity is lacking. The goal of the REPAIR trial is to determine the maximally tolerated dose (MTD) of reirradiation in the thorax, implemented by sequentially increasing the normal tissue recovery factors applied to previously delivered dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multi-institution phase I dose-escalation study for patients undergoing thoracic reirradiation will use a time-to-event continual reassessment method (TITE-CRM). The MTD of reirradiation in this trial is represented by the recovery factor equation associated with a 35% or lower rate of Common Terminology Criteria for Adverse Events (CTCAE) grade 3\u20135 treatment-related toxicity occurring within 1\u00a0year of treatment. Accrual will start at level 1 (recovery factor\u2009=\u200910% at 6\u00a0months\u2009+\u20090.75% per month thereafter). Patients (n\u2009=\u200948) will be assigned to recovery factors using the TITE-CRM model. The model will use all available information from previously accrued patients to assign the highest dose with a predicted risk of grade 3\u20135 toxicity of 35% or less. Patients with recurrence, metastasis, or new primary malignancies in the thorax requiring radiation and who have previously received radiotherapy to the thorax, where reirradiation is expected to exceed the dose constraints used for de novo treatments, are eligible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study will provide information on the safety of dose escalation for thoracic reirradiation using the concept of recovery after radiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov identifier: NCT06558175 (registration date August 14, 2024).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15942-2","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T01:24:39Z","timestamp":1776993879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re-evaluating previous dose and allowing increasing recovery (REPAIR): study protocol for a thoracic reirradiation phase I dose escalation trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Donna H.","family":"Murrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Andratschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanah M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Brock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliaksandr","family":"Karotki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Vickress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X. Melody","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"15942_CR1","doi-asserted-by":"publisher","unstructured":"Willmann J, Appelt L, Balermpas P, Baumert G, de Ruysscher D, Hoyer M, et al. Re-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform. Radiotherapy and Oncology. 2023;189. https:\/\/doi.org\/10.1016\/j.radonc.2023.109947.","DOI":"10.1016\/j.radonc.2023.109947"},{"key":"15942_CR2","doi-asserted-by":"crossref","unstructured":"Andratschke N, Willmann J, Phd T-L, Leeds )\u202f;, Andratschke N, Willmann J, et al. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. Lancet Oncology. 2022;23:469\u201378.","DOI":"10.1016\/S1470-2045(22)00447-8"},{"key":"15942_CR3","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ijrobp.2021.01.041","volume":"110","author":"WT Ng","year":"2021","unstructured":"Ng WT, Soong YL, Ahn YC, AlHussain H, Choi HCW, Corry J, et al. International recommendations on reirradiation by intensity modulated radiation therapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2021;110:682\u201395. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.01.041.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15942_CR4","doi-asserted-by":"publisher","unstructured":"Rulach R, Ball D, Chua KLM, Dahele M, De Ruysscher D, Franks K, et al. An International Expert Survey on the Indications and Practice of Radical Thoracic Reirradiation for Non-Small Cell Lung Cancer. Adv Radiat Oncol. 2021;6. https:\/\/doi.org\/10.1016\/j.adro.2021.100653.","DOI":"10.1016\/j.adro.2021.100653"},{"key":"15942_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.radonc.2021.09.010","volume":"164","author":"F Slevin","year":"2021","unstructured":"Slevin F, Aitken K, Alongi F, Arcangeli S, Chadwick E, Chang AR, et al. An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. Radiother Oncol. 2021;164:104\u201314. https:\/\/doi.org\/10.1016\/j.radonc.2021.09.010.","journal-title":"Radiother Oncol"},{"key":"15942_CR6","doi-asserted-by":"publisher","unstructured":"Jereczek-Fossa BA, Marvaso G, Zaffaroni M, Gugliandolo SG, Zerini D, Corso F, et al. Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. Cancer Treatment Reviews. 2021;98. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102206.","DOI":"10.1016\/j.ctrv.2021.102206"},{"key":"15942_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.ijrobp.2004.06.016","volume":"61","author":"C Nieder","year":"2005","unstructured":"Nieder C, Grosu AL, Andratschke NH, Molls M. Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients. Int J Radiat Oncol Biol Phys. 2005;61:851\u20135. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.06.016.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15942_CR8","doi-asserted-by":"publisher","unstructured":"Nieder C, Grosu AL, Andratschke NH, Molls M. Update of human spinal cord reirradiation tolerance based on additional data from 38 patients. Int J Radiat Oncol Biol Phys. 2006;66:1446\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.07.1383.","DOI":"10.1016\/j.ijrobp.2006.07.1383"},{"key":"15942_CR9","doi-asserted-by":"publisher","unstructured":"Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation Dose-Volume Effects in the Spinal Cord. Int J Radiat Oncol Biol Phys. 2010;76 3 SUPPL. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.04.095.","DOI":"10.1016\/j.ijrobp.2009.04.095"},{"key":"15942_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijrobp.2010.08.021","volume":"82","author":"A Sahgal","year":"2012","unstructured":"Sahgal A, Ma L, Weinberg V, Gibbs IC, Chao S, Chang UK, et al. Reirradiation human spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82:107\u201316. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.08.021.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15942_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijrobp.2019.09.038","volume":"110","author":"A Sahgal","year":"2021","unstructured":"Sahgal A, Chang JH, Ma L, Marks LB, Milano MT, Medin P, et al. Spinal cord dose tolerance to stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2021;110:124\u201336. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.09.038.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15942_CR12","doi-asserted-by":"crossref","unstructured":"Iqbal MS, West N, Richmond N, Kovarik J, Gray I, Willis N, et al. Systematic Review A systematic review and practical considerations of stereotactic body radiotherapy in the treatment of head and neck cancer. 2021. https:\/\/academic.oup.com\/bjr\/article-abstract\/94\/1117\/20200332\/7460354?redirectedFrom=fulltext&login=false.","DOI":"10.1259\/bjr.20200332"},{"issue":"2S","key":"15942_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.02.583","volume":"108","author":"C Simone","year":"2020","unstructured":"Simone C, Amini A, Chetty I, Choi JI, Chun S, Donington J, et al. American Radium Society (ARS) and American College of Radiology (ACR) Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2020;108(2S):E48.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15942_CR14","doi-asserted-by":"crossref","unstructured":"Troost GC, Wink KCJ, Roelofs E, Simone Ii CB, Makocki S, L\u00f6ck S, et al. Photons or protons for reirradiation in (non-)small cell lung cancer: results of the multicentric ROCOCO in silico study. British Journal of Radiology. 2020;93. https:\/\/academic.oup.com\/bjr\/article-abstract\/93\/1107\/20190879\/7449348?redirectedFrom=fulltext&login=false.","DOI":"10.1259\/bjr.20190879"},{"key":"15942_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.adro.2019.05.007","volume":"4","author":"KC Paradis","year":"2019","unstructured":"Paradis KC, Mayo C, Owen D, Spratt DE, Hearn J, Rosen B, et al. The special medical physics consult process for reirradiation patients. Adv Radiat Oncol. 2019;4:559\u201365. https:\/\/doi.org\/10.1016\/j.adro.2019.05.007.","journal-title":"Adv Radiat Oncol"},{"key":"15942_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.lungcan.2013.12.006","volume":"83","author":"GHMJ Griffioen","year":"2014","unstructured":"Griffioen GHMJ, Dahele M, De Haan PF, Van de Ven PM, Slotman BJ, Senan S. High-dose, conventionally fractionated thoracic reirradiation for lung tumors. Lung Cancer. 2014;83:356\u201362. https:\/\/doi.org\/10.1016\/j.lungcan.2013.12.006.","journal-title":"Lung Cancer"},{"key":"15942_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.lungcan.2015.02.008","volume":"88","author":"S Tetar","year":"2015","unstructured":"Tetar S, Dahele M, Griffioen G, Slotman B, Senan S. High-dose conventional thoracic re-irradiation for lung cancer: updated results. Lung Cancer. 2015;88:235\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2015.02.008.","journal-title":"Lung Cancer"},{"key":"15942_CR18","doi-asserted-by":"publisher","unstructured":"Wang HH, Chen Y, Liu X, Zaorsky NG, Mani K, Niu ZM, et al. Reirradiation with stereotactic body radiotherapy for primary or secondary lung malignancies: Tumor control probability and safety analyses. Radiotherapy and Oncology. 2023;187. https:\/\/doi.org\/10.1016\/j.radonc.2023.109817.","DOI":"10.1016\/j.radonc.2023.109817"},{"key":"15942_CR19","doi-asserted-by":"publisher","unstructured":"Gabrys D, Kulik R, Namys\u0142-Kaletka A. Re-irradiation for intra-thoracic tumours and extra-thoracic breast cancer: dose accumulation, evaluation of efficacy and toxicity based on a literature review. British Journal of Radiology. 2022;95. https:\/\/doi.org\/10.1259\/bjr.20201292.","DOI":"10.1259\/bjr.20201292"},{"key":"15942_CR20","doi-asserted-by":"publisher","unstructured":"Lee TH, Kim DY, Wu HG, Lee JH, Kim HJ. Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis. Radiation Oncology. 2021;16. https:\/\/doi.org\/10.1186\/s13014-021-01948-6.","DOI":"10.1186\/s13014-021-01948-6"},{"key":"15942_CR21","doi-asserted-by":"publisher","unstructured":"Maddalo M, D\u2019Angelo E, Fiorica F, Argenone A, Scricciolo M, Cozzi S, et al. Thoracic re-irradiation with 3D-conformal or more advanced techniques: A systematic review of treatment safety by the Re-irradiation Study Group of the Italian Association of Radiation and Oncology AIRO. Critical Reviews in Oncology\/Hematology. 2021;167. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103500.","DOI":"10.1016\/j.critrevonc.2021.103500"},{"key":"15942_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.radonc.2020.07.033","volume":"152","author":"C Schr\u00f6der","year":"2020","unstructured":"Schr\u00f6der C, Stiefel I, Tanadini-Lang S, Pytko I, Vu E, Guckenberger M, et al. Re-irradiation in the thorax \u2013 an analysis of efficacy and safety based on accumulated EQD2 doses. Radiother Oncol. 2020;152:56\u201362. https:\/\/doi.org\/10.1016\/j.radonc.2020.07.033.","journal-title":"Radiother Oncol"},{"key":"15942_CR23","unstructured":"De Ruysscher D, Faivre-Finn C, Le Pechoux C, Peeters S, Belderbos J. Review High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer. 2014. https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(14)70345-6\/fulltext."},{"key":"15942_CR24","doi-asserted-by":"publisher","unstructured":"John C, Dal Bello R, Andratschke N, Guckenberger M, Boda-Heggemann J, Gkika E, et al. In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO). Sci Rep. 2021;11. https:\/\/doi.org\/10.1038\/s41598-021-83210-3.","DOI":"10.1038\/s41598-021-83210-3"},{"key":"15942_CR25","doi-asserted-by":"publisher","unstructured":"Rock C, Kane K, Sood S, Cao Y, Chen RC, Wang F. Reirradiation of Utracentrally Located Thoracic Tumors Using a 10-Fraction Hypofractionated Stereotactic Body Radiation Therapy Course: A Detailed Dosimetric Analysis. Adv Radiat Oncol. 2024;9. https:\/\/doi.org\/10.1016\/j.adro.2024.101626.","DOI":"10.1016\/j.adro.2024.101626"},{"key":"15942_CR26","unstructured":"NRGOncology. RTOG 0813 Seamless phase I\/II study of stereotactic lung radiotherapy (SBRT) for early stage, centrally located, non-small cell lung cancer (NSCLC) in medically inoperable patients. 2015. https:\/\/wwwnrgoncology.org\/Clinical-Trials\/Protocol\/rtog-0813\/."},{"key":"15942_CR27","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","volume":"19","author":"M Giuliani","year":"2018","unstructured":"Giuliani M, Mathew AS, Bahig H, Bratman SV, Filion E, Glick D, et al. SUNSET: stereotactic radiation for ultracentral non\u2013small-cell lung cancer\u2014a safety and efficacy trial. Clin Lung Cancer. 2018;19:e529\u201332. https:\/\/doi.org\/10.1016\/j.cllc.2018.04.001.","journal-title":"Clin Lung Cancer"},{"key":"15942_CR28","unstructured":"TITE-CRM Phase I Clinical Trials: Implementation Using SAS. https:\/\/sph.umich.edu\/ccb\/pdf\/titecrm_manual_1-5-09.pdf."},{"key":"15942_CR29","doi-asserted-by":"publisher","unstructured":"Brock KK, Sharpe MB, Dawson LA, Kim SM, Jaffray DA. Accuracy of finite element model-based multi-organ deformable image registration. In: Medical Physics. John Wiley and Sons Ltd; 2005. p. 1647\u201359. https:\/\/doi.org\/10.1118\/1.1915012.","DOI":"10.1118\/1.1915012"},{"key":"15942_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1118\/1.4938412","volume":"43","author":"N Samavati","year":"2016","unstructured":"Samavati N, Velec M, Brock KK. Effect of deformable registration uncertainty on lung SBRT dose accumulation. Med Phys. 2016;43:233\u201340. https:\/\/doi.org\/10.1118\/1.4938412.","journal-title":"Med Phys"},{"key":"15942_CR31","doi-asserted-by":"publisher","unstructured":"He Y, Cazoulat G, Wu C, Svensson S, Almodovar-Abreu L, Rigaud B, et al. Quantifying the effect of 4-dimensional computed tomography\u2013based deformable dose accumulation on representing radiation damage for patients with locally advanced non-small cell lung cancer treated with standard-fractionated intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2024;118:231\u201341. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.07.016.","DOI":"10.1016\/j.ijrobp.2023.07.016"},{"key":"15942_CR32","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1088\/0031-9155\/61\/13\/4826","volume":"61","author":"G Cazoulat","year":"2016","unstructured":"Cazoulat G, Owen D, Matuszak MM, Balter JM, Brock KK. Biomechanical deformable image registration of longitudinal lung CT images using vessel information. Phys Med Biol. 2016;61:4826\u201339. https:\/\/doi.org\/10.1088\/0031-9155\/61\/13\/4826.","journal-title":"Phys Med Biol"},{"key":"15942_CR33","doi-asserted-by":"publisher","unstructured":"Hardcastle N, Vasquez Osorio E, Jackson A, Mayo C, Aarberg AE, Ayadi M, et al. Multi-centre evaluation of variation in cumulative dose assessment in reirradiation scenarios. Radiotherapy and Oncology. 2024;194. https:\/\/doi.org\/10.1016\/j.radonc.2024.110184.","DOI":"10.1016\/j.radonc.2024.110184"},{"key":"15942_CR34","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.clon.2022.02.010","volume":"34","author":"P Diez","year":"2022","unstructured":"Diez P, Hanna GG, Aitken KL, van As N, Carver A, Colaco RJ, et al. UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy. Clin Oncol. 2022;34:288\u2013300. https:\/\/doi.org\/10.1016\/j.clon.2022.02.010.","journal-title":"Clin Oncol"},{"key":"15942_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"JD Bradley","year":"2015","unstructured":"Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187\u201399. https:\/\/doi.org\/10.1016\/S1470-2045(14)71207-0.","journal-title":"Lancet Oncol"},{"key":"15942_CR36","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/j.0006-341x.2000.01177.x","volume":"56","author":"YK Cheung","year":"2000","unstructured":"Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000;56:1177\u201382. https:\/\/doi.org\/10.1111\/j.0006-341x.2000.01177.x.","journal-title":"Biometrics"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15942-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15942-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15942-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:38:17Z","timestamp":1781649497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15942-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15942"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15942-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was granted from the Ontario Cancer Research Ethics Board (#4968). Additional sites opening the trial will pursue ethics approval from their jurisdictions. All participants will provide written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"David Palma reports research funding from the Ontario Institute for Cancer Research, royalties from UptoDate.com, and has a consultant role with equity with Need Inc, unrelated to the current study. Kristy Brock reports research funding from RaySearch Laboratories. Alexander Louie reports speaker\u2019s bureau and advisory board participation from AstraZeneca. All other authors report no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"724"}}